2021: Food Assistance Program.
We are currently accepting applications from women with advanced/metastatic cancer who live in Greater Houston and need assistance to buy groceries. If you are interested in applying, please contact us at firstname.lastname@example.org or call us at 713-661-4045.
June 4-8, 2021: Angelmira's Center for Women with Advanced Cancer participated in the annual meeting of the American Society of Clinical Oncology (ASCO).
May 17-21, 2021: Angelmira's Center for Women with Advanced Cancer participated in the annual meeting of the American Association for Cancer Research (Week 2) and in the Scientist-Survivor Program 2021.
May 12, 2021: Members of our Board of Directors delivered 30 care packages to be given to women recently diagnosed with cancer at the Harris Health System (Harris County hospitals/clinics).
April 9-15, 2021: Angelmira's Center for Women with Advanced Cancer participated in the annual meeting of the American Association for Cancer Research (Week 1) and in the Scientist-Survivor Program 2021.
April 7, 2021: The FDA has granted a regular approval to sacituzumab govitecan (Trodelvy) for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer. FDA had previously granted accelerated approval to this Trop-2 directed antibody and topoisomerase inhibitor drug conjugate (April 2020).
March 26, 2021: Angelmira’s Center for Women with Advanced Cancer has been accepted as a nonprofit member of the Metastatic Breast Cancer Alliance. We are proud to be part of this wonderful group working to improve quality of life and survival outcomes of people affected by metastatic breast cancer.
January 14, 2021: Members of our Board of Directors delivered 30 cancer care packages to be given to women recently diagnosed with cancer at the Harris Health System (Harris County hospitals/clinics).
December 29, 2020: Angelmira's Center for Women with Advanced Cancer received a generous grant from the Silicon Valley Community Foundation. This grant will support the mission of the center of helping women with advanced cancer in need of companionships and other resources.
December 8-11, 2020: Angelmira's Center presented a scientific poster at the 2020 San Antonio Breast Cancer Symposium (SABCS) and participated in the 2020 Alamo Advocate Program.
November 20, 2020: The FDA approved Durvalumab for fixed-dose use in non-small cell lung cancer and bladder cancer indications.
November 13, 2020: Breast Cancer News- The FDA granted an accelerated approval to pembrolizumab for use in combination with chemotherapy in the treatment of patients with metastatic triple-negative breast cancer whose tumors express PD-L1 as determined by an FDA-approved test.
November 10-12, 2020: Angelmira's Center for Women with Advanced Cancer participated in the Virtual Texas Life Science Forum organized by the Rice Alliance and BioHouston.
November 7, 2020: Lily and Maricarmen participated in the MD Anderson Boot Walk to Stomp out Stage IV Breast Cancer by walking 3 miles together. Angelmira's Center for Women with Advanced Cancer raised funds for the Advanced Breast Cancer Program (ABC) at MD Anderson. This program supports women with advanced or stage IV breast cancer.
September 2020: Our President Maricarmen received her Oncology Patient Navigation Certificate
March 2020: Our secretary presented our scientific abstract on the impact of obesity on survival of women with metastatic breast cancer at the United States and Canadian Association of Pathology (USCAP) 2020 meeting.
December 2019: We presented our scientific research at the San Antonio Breast Cancer Symposium (SABCS) 2019. This translational research was done in collaboration with investigators at the University of Rochester Medical Center.
September 2019: Our president and founder participated at a local health fair on behalf of Angelmira's Center, providing information on advanced breast cancer and other cancer types in women. (Educational material provided by American Cancer Society and Susan G. Komen-Houston.)
April 22, 2021: The FDA has granted an accelerated approval to dostarlimab-gxly for the treatment of select patients with recurrent or advanced endometrial cancer.